Editas Medicine, Inc. (NASDAQ: EDIT) is a clinical-stage company specializing in genome editing, with a focus on developing transformative treatments for serious diseases. The company’s
Editas Medicine, Inc. (EDIT) is a leading genome editing company engaged in translating the potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing platforms into a
Editas Medicine, Inc. (EDIT) saw a decrease of 7.04% in aftermarket following the update in SEC filing. However, the last trading session concluded at $19.32
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.